Asimov


Provides an integrated genetic-design platform that combines computational design software, machine-learning models, validated genetic parts, engineered host cells, and cell line and upstream process development. Offers GMP-compliant banked host cells and documentation, DNA construction and QC services, engineered transposase integration tools, and lab-in-the-loop AI workflows to support development of biologics, viral vectors, gene therapies, and RNA therapeutics.

Industries

Artificial Intelligence
Artificial Intelligence (AI)
Biotechnology
Software
Therapeutics
Biotechnology Research

Nr. of Employees

medium (51-250)

Asimov

Boston, Massachusetts, United States


Products

GMP-compliant production host cell lines

Engineered, characterized host cell lines supplied with documentation suitable for therapeutic production workflows.

Validated genetic parts library and vector templates

A curated collection of experimentally validated genetic parts and engineered vector layouts used as templates for construct design and gene expression control.

Engineered transposase-based integration tool (licensed)

Engineered transposase system available for licensing to enable stable genomic integration for cell engineering and rapid generation of stable production material.

AAV production system and host cell workflows

A packaged AAV production offering including a transient two-plasmid production approach, compatible host systems, and model-guided process improvements for increased unconcentrated titers.


Services

Develop commercial-grade cell lines and upstream processes at provider facilities and deliver clonal cell banks and process documentation to customers.

Licensed access to design software, engineered host cells, and genetic tools for in-house use, or delivery of licensed modules for internal deployment.

Construct, sequence-verify, perform quality control, and ship plasmid DNA to customer facilities.

Provide AI and data-driven modeling services and lab-in-the-loop workflows to optimize sequence designs, expression, and production conditions across modalities including RNA, AAV, and biologics.

Support for AAV and lentiviral production including transient manufacturing systems, process optimization, and transfers to manufacturing partners.

Expertise Areas

  • Computational genetic design
  • Cell line development and clonal selection
  • Biologics expression optimization (CHO systems)
  • Viral vector development and manufacture (AAV, lentivirus)
  • Show More (4)

Key Technologies

  • Cloud-based genetic design and collaboration
  • Hybrid mechanistic and machine-learning modeling
  • Lab-in-the-loop experimental automation
  • Transposase-mediated genomic integration
  • Show More (5)

News & Updates

Announcement that the company's AI-driven cell line development platform was adopted by LG Chem under a licensing or partnership agreement.

Announcement of an engineered transposase system optimized for stable integration, improved expression stability, and rapid generation of stable material.

Announcement of a lab-in-the-loop AI platform to iteratively optimize RNA therapeutic candidates using integrated modeling and experimental cycles.

Announcement of an integrated suite of models, host cell systems, and genetic tools for end-to-end AAV gene therapy design and production, including a transient two-plasmid production system.

Funding raise to support development of an integrated therapeutics design and manufacturing platform using synthetic biology approaches.

Participation in a cloud-lab initiative to support lab-in-the-loop AI models by integrating remote experimental infrastructure for model validation and training.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.